Quarterly Performance: $ABUS $IDEX $CBAY

*If You Own ABUS, IDEX, CBAY Then Click Here to Join Our Community Of Traders

The Market Signal was created as a platform to help investors, if you own (NASDAQ:ABUS), (NASDAQ:IDEX) or (NASDAQ:CBAY) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.


(Click link above or copy, paste and hit enter in your browser for your report)

Arbutus Biopharma gears up for its Q 2020 financials

https://themarketsignal.com/ Free-Report/ABUS

(Click link above or copy, paste and hit enter in your browser for your report)

Arbutus Biopharma Corp (NASDAQ:ABUS) stock rallied by 194.37% in Q2, thus demonstrating impressive performance.

The company is scheduled to release its financial report for Q2 2020 on Friday, August 7 and analysts expect positive results especially given the stock performance during the quarter. The expectations are mainly guided by the recovery especially after the huge economic downturn caused by the coronavirus in the first quarter. The Q2 financials will be announced through a live webcast which can be accessed on the company's website, www.arbutusbio.com

Ideanomics to release its Q2 2020 financial report on August 10, deadline for the company's class-action suit set

https://themarketsignal.com/ Free-Report/IDEX

(Click link above or copy, paste and hit enter in your browser for your report)

Ideanomics Inc (NASDAQ:IDEX) experienced a 198.95% gain in its share value in Q2 2020.

The company revealed on August 5 that it will hold the press conference on August 10, during which it will announce its financial results for the second quarter of 2020. This means that the schedule for the Q2 financials has been moved forward by one day since the company had previously planned to hold to conference on August 11.

Ideanomics also revealed that investors have until August 2017 this year to file for appointment as the lead plaintiff in the class-action lawsuit against the company. The Southern District of New York filed the lawsuit on behalf of investors that purchased the company's stock. The case was titled Lundy v. Ideanomics, Inc., No. 20-cv-04944 and it will be presided by Judge George B. Daniels. The invitation allows any of the shareholders that purchased Ideonomics stock to apply for the lead plaintiff position.

CymaBay Therapeutics to release its Q2 financial earnings report on August 10, PBC treatment achieves targeted results

https://themarketsignal.com/ Free-Report/CBAY

(Click link above or copy, paste and hit enter in your browser for your report)
CymaBay Therapeutics Inc (NASDAQ:CBAY) stock gained by 186.10% in Q2 2020.

CymaBay released a statement on August 3, in which it stated that it plans to release its Q2 2020 financial results on August 10. The company also revealed that it will also provide a business update on the same day that it announces the Q2 financials. Investors can access the conference through the company's website. Canadian or international investors can access the conference by dialing 201-689-8560 and U.S-based investors can access it by dialing 877-407-0784.

CymaBay also reported some more good news on August 3. It announced that its pipeline biliary cholangitis (PBC) treatment called seladelpar achieved the set targets in its Phase III study. The company expressed excitement about the study findings because the results increase the chances of securing regulatory approval as a PBC treatment. The company's CEO, Sujal Shah revealed in a statement that the pipeline treatment's topline data for patients treated with seladelpar for 12 to 26 weeks highlights the treatment's anti-inflammatory, anti-pruritic and anti-cholestatic activity.

Seladelpar has already received orphan designation as a PBC treatment from the FDA in the U.S and the European Medicine Agency in Europe. It also bagged Breakthrough Therapy Destination from the FDA.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.


The post Quarterly Performance: $ABUS $IDEX $CBAY appeared first on The Market Signals.

comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.